-+ 0.00%
-+ 0.00%
-+ 0.00%

UroGen Pharma Shares Results From 5-Year Follow-Up Study On Olympus

Benzinga·10/28/2026 12:05:05
  • Five-year Olympus follow-up data published in Therapeutic Advances in Urology reinforce the long-term durability of response with JELMYTO
  • Results demonstrate sustained disease control through extended follow-up among patients who achieved a complete response after treatment with JELMYTO
  • No progression to high-grade disease was observed during extended follow-up